(firstQuint)A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM).

 The regimen being tested in this study is the combination of ixazomib, daratumumab, and dexamethasone.

 This study will look at the efficacy and safety of Ixazomib + Daratumumab + Dexamethasone (IDd) in people who have relapsed and/or refractory multiple myeloma (RRMM).

 The study will enroll approximately 60 patients.

 Participants will be assigned to the treatment group: cent Ixazomib 4.

0 mg + Daratumumab 16.

0 mg/kg + Dexamethasone 20 mg All participants will be asked to take Ixazomib on Days 1, 8 and 15 of each 28-day cycle plus Daratumumab on Days 1, 8, 15 and 22 of each 28-day cycle for Cycles 1 and 2, on Days 1 and 15 of each 28-day cycle for Cycles 3 through 6 and on Day 1 of each 28-day cycle for Cycle 7 and beyond plus Dexamethasone orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle.

 This multi-center trial will be conducted worldwide.

 The overall time to participate in this study is 5 years.

 Participants will make multiple visits to the clinic, and every 12 weeks after PD until death or termination of the study by the sponsor.

.

 A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)@highlight

The purpose of this study is to evaluate the efficacy and safety of ixazomib in combination with daratumumab and dexamethasone in participants with relapsed and/or refractory myeloma.

